Timothy Sharpington

Cambridge Innovation Capital Ltd (Cambridge Innovation Capital) is a venture capital firm founded in 2013. The firm is headquartered in Cambridge, United Kingdom.

Activiomics Ltd. develops innovative technologies that utilize mass spectrometry to interrogate and interpret the activity of cellular signaling pathways. It offers phosphoproteomics for biomaker discovery and drug profiling. The company was founded by Bart Vanhaesebroeck and Pedro Rodriguez Cutillas in 2009 and is headquartered in London, the United Kingdom.

Exvastat Ltd. operates as pharmaceutical company. The firm develops treatment for acute respiratory distress syndrome (ARDS) based on a repurposed drug which is marketed worldwide for other indications. The company was founded by David Cavalla , Charlotte Summers and Andrew McElroy in 2016 and is headquartered in Cambridge, the United Kingdom.

Health Clinics Ltd. offers medical treatment. It offers cancer treatment, cancer research and repurposed medicines. The company is headquartered in London, the United Kingdom.

Sosei R&D Ltd. manufactures pharmaceutical products. It develops and commercializes product opportunities based upon clinical uses for known drugs and templates. The company was founded by Julian Gilbert and Robin Bannister in March, 2000 and is located in Saffron Walden, the United Kingdom.

InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands.

Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland.

Therachon Holding GmbH engages in the acquisition, management, financing, and disposal of participating interests in firms. It also acquires, holds, and disposes intellectual property rights. The company was founded on December 22, 2015 and is headquartered in Basel, Switzerland.

INIM Pharma AB operates as drug development company that focuses on the development of immunomodulatory drugs for interstitial lung diseases. It develops a new local treatment for severe rare lung diseases such as idiopathic pulmonary fibrosis. The company was founded by Carl-Johan Dalsgaard and is headquartered in Stockholm, Sweden.

VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland.

Pharvaris GmbH operates as a clinical-stage company. It specializes in medicinal chemistry, drug discovery and development and hereditary angioedema. The company was founded by Berndt A. E. Modig, Jochen Knolle, Anne Lesage and Hans G. C. P. Schikan in October 2015 and is headquartered in Zug, Switzerland.

Part of Tripos, Inc., Receptor Research Ltd. provides drug discovery informatics products and services. The private company is based in Bude, UK. Receptor Research was acquired by Tripos, Inc. on November 18, 1997.

The Royal Society of Chemistry is an organization that supports the chemical sciences community in making the world a better place. The Royal Society of Chemistry is based in London, UK, and has subsidiaries in the United Kingdom. The British company offers various opportunities in education, inclusion, and chemistry's ability to tackle challenges. The organization aims to advance excellence, connect chemical scientists, and shape the future of the chemical sciences for the benefit of humanity. The private company has a publishing portfolio that contains over one million articles, chapters, and records from across the chemical sciences and related fields. The company also provides solutions to help businesses engage with their audience of chemical scientists.

Iksuda Therapeutics Ltd. operates as a biotechnology company which specializes in the development of next generation biotherapeutics. It creates new generation biological therapeutics through advanced glycosylation and conjugation technologies. The company has core expertise in protein/peptide fictionalization and glycosylation technologies, imparting improved pharmacokinetic properties to a broader range of biological therapeutics. It was founded by David John Simpson and Andrew Watts on November 21, 2007 and is headquartered in Newcastle upon Tyne, the United Kingdom.

Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers.

Complix NVengages in the development of biopharmaceutical company developing Alphabodies, a pipeline of transformative protein therapeutics. The Company is currently focusing its internal research and development activities on oncology and autoimmune diseases. Its therapeutic Alphabodies focuses on the treatment of autoimmune diseases, such as rheumatoid arthritis, psoriasis and multiple sclerosis, and infectious diseases, and viral diseases such as influenza, HIV, and RSV. The company was founded by Mark Vaeck and Ignace Lasters in 2008 and is headquartered in Diepenbeek, Belgium.

Part of EXEL Industries SA, Rasindeck Ltd. is a British company founded in 1998 that provides a new soft-touch lightweight woven hose called Wonderhoze. The private company is based in Sutton Coldfield, UK and offers gardening solutions to help gardens flourish and come to life. The hose is designed to provide comfort when watering and is compact and flexible, expanding up to 3 times its original length. The key benefits of Wonderhoze include a strong soft-touch woven fabric layer, guaranteed leak-free fittings, and a water-tight connection. Hozelock, the parent company, combines a knowledge and passion for gardening, and pride in product craftsmanship.

Part of EXEL Industries SA, Thistlehaven Ltd. operates as a holding British company. The private company is based in Sutton Coldfield, UK.

Part of Watkin Jones Plc, Watkin Jones Group Ltd. is a British company that develops building projects. The private company is based in Bangor, UK. The company was founded in 1791 by Huw Jones. Mark Watkin Jones has been the CEO of the company since 2003.

Part of Sanofi, Genzyme Europe BV is a Dutch company that develops and manufactures pharmaceutical and biotherapeutic products. The private company is based in Amsterdam, Netherlands.